Results 221 to 230 of about 199,961 (298)

Virus Biomimetic-Delivery Systems for the Production of Vaccines. [PDF]

Biomimetics (Basel)
Barbinta-Patrascu ME, Negut I, Bita B.
europepmc   +1 more source

Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects

Advanced Science, EarlyView.
Bacterial outer membrane vesicles (OMVs) have emerged as versatile platforms for cancer vaccine development owing to their intrinsic immunostimulatory properties and high engineering flexibility. This review summarizes OMV biology, immune mechanisms, and engineering strategies that enhance vaccine efficacy, discusses key translational challenges, and ...
Jiabeini Zhang, Tianyu Shao, Fengjiang Qu, Caiyun Bai, Sijie Li, Pin Gao, Wenna Li, Keman Cheng, Xiao Zhao, Zhimin Fan   +9 more
wiley   +1 more source

Conservation of Bacterial Lipopolysaccharide Binding by SARS-CoV-2 Spike across Major Viral Variants. [PDF]

Comput Struct Biotechnol J
Samsudin F, Petruk G, Rui L, Schmidtchen A, Bond PJ.   +4 more
europepmc   +1 more source

Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer

Advanced Science, EarlyView.
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu, Miaoyan Wei, Rong Tang, Xianjun Yu, Si Shi   +13 more
wiley   +1 more source

Opportunities and challenges for cancer immunotherapy based on antigen cross-presentation. [PDF]

Ann Med
Liu P, Zhou Z, Su X, Xu Y, Li J.
europepmc   +1 more source

Lipoic Acid‐Intervened Decellularized Stem Cell Spheroid‐Based Injectable Granular Gel for Diabetic Tissue Regeneration

Advanced Science, EarlyView.
ABSTRACT Advancements in tissue engineering have revolutionized therapeutic paradigms for diabetic tissue defects; however, the lack of applicable scaffold containing various bioactive substance aggregates remained a critical bottleneck hindering satisfactory repair effect.
Tao Wang, Haowei Fang, Lili Qi, Song Myoungseop, Aawrish Khan, Lunli Gong, Guangdong Zhou, Kunxi Zhang, Haiyan Cui   +8 more
wiley   +1 more source

Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy

Advanced Science, EarlyView.
Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Joonha Lee, Chul‐Gyun Lim, Pothiappan Vairaprakash, Jong‐Min Kim, Jiyoon Kim, Ji‐Young Park, Klaus M. Hahn, Hyunbo Shim, Hae Woong Choi, Tobias S. Ulmer, Soon Jun Hong, Chungho Kim   +11 more
wiley   +1 more source

Targeting metabolic reprogramming to enhance adoptive immunotherapy: emerging mechanisms and translational perspectives. [PDF]

J Transl Med
Yang L, Zhang C, Zhang Z, Yao S, Shen J, Zhang Z, Xiao Z, Wang S, Wu Z.   +8 more
europepmc   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source